Mirum Pharmaceuticals, Inc.

Informe acción NasdaqGM:MIRM

Capitalización de mercado: US$1.2b

Salud financiera de hoja de balance de Mirum Pharmaceuticals

Salud financiera controles de criterios 4/6

Mirum Pharmaceuticals tiene un patrimonio de los accionistas total de $248.7M y una deuda total de $306.4M, lo que sitúa su ratio deuda-patrimonio en 123.2%. Sus activos y pasivos totales son $646.6M y $398.0M respectivamente.

Información clave

123.2%

Ratio deuda-patrimonio

US$306.42m

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$286.33m
PatrimonioUS$248.67m
Total pasivoUS$397.95m
Activos totalesUS$646.62m

Actualizaciones recientes sobre salud financiera

Is Mirum Pharmaceuticals (NASDAQ:MIRM) In A Good Position To Invest In Growth?

Apr 22
Is Mirum Pharmaceuticals (NASDAQ:MIRM) In A Good Position To Invest In Growth?

Recent updates

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Apr 22

Mirum Pharmaceuticals: Advancing On Several Key Fronts

Mar 05

There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

Dec 26
There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Jun 10
What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Apr 18
Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU

Oct 14

Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth

Aug 17

Mirum Pharmaceuticals announces $80M stock offering

Aug 09

Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent

May 27

Is Mirum Pharmaceuticals (NASDAQ:MIRM) In A Good Position To Invest In Growth?

Apr 22
Is Mirum Pharmaceuticals (NASDAQ:MIRM) In A Good Position To Invest In Growth?

Mirum Pharmaceuticals Gets The 'Thumbs Up'

Dec 16

Need To Know: Analysts Just Made A Substantial Cut To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates

Nov 25
Need To Know: Analysts Just Made A Substantial Cut To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates

Mirum And Maralixibat In Pediatric Cholestasis: The Differentiation

Aug 24

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($387.5M) de MIRM superan a sus pasivos a corto plazo ($87.1M).

Pasivo a largo plazo: Los activos a corto plazo de MIRM ($387.5M) superan a sus pasivos a largo plazo ($310.9M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (8.1%) de MIRM se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de MIRM ha crecido de 0% a 123.2% en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: MIRM tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si MIRM tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.


Descubre empresas con salud financiera

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target